Frexalimab
Frexalimab is an second-generation monoclonal antibody[1] for the treatment of relapsing multiple sclerosis, under developement by Sanofi.[2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | CD40 ligand |
Clinical data | |
AHFS/Drugs.com | Monograph |
License data |
|
Legal status | |
Legal status |
|
Identifiers | |
ChemSpider |
|
KEGG |
Mechanism of action
It is a CD40 ligand inhibitor.[2][1]
See also
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.